Adeno-associated virus (AAV) is the most common vector for gene therapy, yet there’s much room to improve production, purification, and analytics. Here we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a successful process are high overall yields of full capsids with empty capsid reduction and efficient impurity removal.
In this webinar you will learn:
• Common pitfalls for rAAV processing and ways to overcome the challenges
• How the full and empty AAV capsid separation can be significantly improved with one chromatography resin and one protocol for AAV2, AAV5, AAV8 and AAV9